Lurbinectedin showed clinical benefit across therapy lines in SCLC, with best responses seen in later lines and with prior immunotherapy exposure.
The post Second-Line & Later Therapies Show Promising Outcomes in Small Cell Lung Cancer first appeared on Physician’s Weekly.
